View Older Stories View More Recent Stories
-
Eli Lilly to invest another $27 billion in U.S. manufacturing
-
Deutsche Bank Reiterates Buy Rating on Eli Lilly (LLY) Amid New U.S. Investment
-
JPMorgan Reiterates Overweight Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) to more than double U.S. manufacturing investment since 2020 exceeding $50B
-
BMO Capital Reiterates Outperform on Eli Lilly (LLY) After Self Pay Program Expansion
-
Eli Lilly (LLY) Lowers Zepbound Price; Bernstein: 'This is Something We'd Been Hoping to See'
-
Organovo's (ONVO) FXR Program, including FXR314, Acquired by Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) launches additional Zepbound vial doses and offers new savings for self-pay patients
-
Bernstein Sees 'Clear Upside' for Eli Lilly's (LLY) Zepbound and Mounjaro Post FDA Announcement
-
What's the current state of China's GLP-1 market?
-
Eli Lilly & Co. (LLY) call put ratio 3.9 calls to 1 put as share price up 2.2%
-
Eli Lilly & Co. (LLY) call put ratio 1.8 calls to 1 put amid price movement
-
Eli Lilly & Co. (LLY) Files Mixed Shelf
-
Eli Lilly announces $6.5 billion six-part note offering
-
Eli Lilly & Co. (LLY) reports most patients on Omvoh for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
-
Eli Lilly & Co. (LLY) Tops Q4 EPS by 2c; offers outlook
-
Bernstein on Eli Lilly (LLY) Following NOVO Read-Across: 'Good News for LLY'
-
Eli Lilly & Co. (LLY) call put ratio 1.6 calls to 1 put into quarter results
-
Eli Lilly Q4 earnings preview: Here’s what to expect
-
Erste Group Upgrades Eli Lilly (LLY) to Buy
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put into quarter results
-
Eli Lilly (LLY) PT Raised to $1,038 at Truist on 'Updated FY2024 and Announced FY2025 Guidance'
-
Eli Lilly & Co. (LLY), Novo (NVO) see mid-day upside
-
Tectonic shares tumble after rival drug trial termination
-
Leerink Comments on Tectonic Therapeutics Inc. (TECX) Post Eli Lilly (LLY) Terminating volenrelaxin CKD
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY): 'Novo Punches Back, but LLY Still a Step Ahead'
-
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) Morgan Stanley sees three potential scenarios in the compounders vs. FDA over Tirzepatide
-
BofA Adjusts US 1 List
-
Eli Lilly & Co. (LLY) call put ratio 2.1 calls to 1 put
-
BofA Securities Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Lowered to $973 at Guggenheim
-
Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh for Crohn's disease
-
Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY) Despite 'Disappointing' GLP-1 Miss
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Wells Fargo Reiterates Overweight Rating on Eli Lilly (LLY)
-
BofA Securities on Eli Lilly (LLY): 'a particularly good buying opportunity'
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put as share price pulls back
-
Lilly (LLY) provides update on 2024 revenue guidance, announces 2025 revenue guidance
-
Eli Lilly & Co. (LLY) Asks Biden Administration to Pause Drug-price Negotiation - Bloomberg
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Lilly (LLY) to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
-
Eli Lilly (LLY) in advanced talks to buy US cancer biotech for up to $2.5bn - FT
-
Medicare can now cover Eli Lilly’s (LLY) Zepbound for sleep apnea, CMS says - CNBC
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY); ' Near-term, It's All About GLP-1/Obesity'
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
